Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni

PLoS Neglected Tropical Diseases

Volumn 10, Issue 1, 2016, Pages

  Long, Thavy ^a,b,g   Neitz, R Jeffrey ^a,c   Beasley, Rachel ^d   Kalyanaraman, Chakrapani ^c   Suzuki, Brian M ^a,b,g   Jacobson, Matthew P ^c   Dissous, Colette ^e   McKerrow, James H ^a,b,g   Drewry, David H ^f   Zuercher, William J ^f   Singh, Rahul ^a,d   Caffrey, Conor R ^a,b,g  

^a University of California at San Francisco   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO STATE UNIVERSITY   (United States)

^e UNIV LILLE   (France)

^f GLAXOSMITHKLINE   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; BENZIMIDAZOLE THIOPHENE INHIBITOR; PENICILLIN DERIVATIVE; POLO LIKE KINASE 1; STREPTOMYCIN; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATE; ANTISCHISTOSOMAL AGENT; BENZIMIDAZOLE DERIVATIVE; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE;

ARTICLE; GENE EXPRESSION; IC50; INFECTION RISK; MOLECULAR MODEL; NONHUMAN; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HAMSTER; MESOCRICETUS; METABOLISM; PROTEIN CONFORMATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BENZIMIDAZOLES; BINDING SITES; CELL CYCLE PROTEINS; CRICETINAE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MESOCRICETUS; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SCHISTOSOMA MANSONI; SCHISTOSOMICIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84969429408     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004356     Document Type: Article

References (88)

1. WHO. Schistosomiasis: Fact sheet N°115: WHO; 2014. http://www.who.int/mediacentre/factsheets/fs115/en/.
2. Domling A, Khoury K, Praziquantel and schistosomiasis. ChemMedChem. 2010;5(9):1420–34. doi: 10.1002/cmdc.201000202 20677314
3. Abdul-Ghani RA, Loutfy N, Hassan A, Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use. Parasitol Res. 2009;105(4):899–906. doi: 10.1007/s00436-009-1546-2 19588166
4. Cioli D, Pica-Mattoccia L, Basso A, Guidi A, Schistosomiasis control: praziquantel forever? Mol Biochem Parasitol. 2014;195(1):23–9. doi: 10.1016/j.molbiopara.2014.06.002 24955523
5. Caffrey CR, Schistosomiasis and its treatment. Future Med Chem. 2015;7(6):675–6. doi: 10.4155/fmc.15.27 25996057
6. Thetiot-Laurent SA, Boissier J, Robert A, Meunier B, Schistosomiasis chemotherapy. Angew Chem Int Ed Engl. 2013;52(31):7936–56. doi: 10.1002/anie.201208390 23813602
7. Valentim CL, Cioli D, Chevalier FD, Cao X, Taylor AB, Holloway SP, et al. Genetic and molecular basis of drug resistance and species-specific drug action in schistosome parasites. Science. 2013;342(6164):1385–9. doi: 10.1126/science.1243106 24263136
8. Wang W, Wang L, Liang YS, Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012;111(5):1871–7. doi: 10.1007/s00436-012-3151-z 23052781
9. Aragon AD, Imani RA, Blackburn VR, Cupit PM, Melman SD, Goronga T, et al. Towards an understanding of the mechanism of action of praziquantel. Mol Biochem Parasitol. 2009;164(1):57–65. doi: 10.1016/j.molbiopara.2008.11.007 19100294
10. Doenhoff MJ, Cioli D, Utzinger J, Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis. 2008;21(6):659–67. doi: 10.1097/QCO.0b013e328318978f 18978535
11. Caffrey CR, Secor WE, Schistosomiasis: from drug deployment to drug development. Curr Opin Infect Dis. 2011;24(5):410–7. doi: 10.1097/QCO.0b013e328349156f 21734570
12. Olliaro P, Delgado-Romero P, Keiser J, The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother. 2014;69(4):863–70. doi: 10.1093/jac/dkt491 24390933
13. Buhring KU, Diekman HW, Muller H, Garbe A, Nowak H, Metabolism of praziquantel in man. Eur J Drug Metab Pharmacokinet. 1978;3:179–90.
14. Andrews P, Thomas H, Pohlke R, Seubert J, Praziquantel. Med Res Rev. 1983;3(2):147–200. 6408323
15. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ, Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol. 1986;61(3):294–303. 3086114
16. Xiao SH, Yue WJ, Yang YQ, You JQ, Susceptibility of Schistosoma japonicum to different developmental stages to praziquantel. Chin Med J (Engl). 1987;100(9):759–68.
17. Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C, Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis. 2009;3(1):e357. doi: 10.1371/journal.pntd.0000357 19159015
18. Geary TG, Sakanari J, Caffrey CR, Anthelmintic drug discovery: into the future. J Parasitol. 2015;101(2):125–33. doi: 10.1645/14-703.1 25584662
19. Neves BJ, Andrade CH, Cravo PV, Natural products as leads in schistosome drug discovery. Molecules. 2015;20(2):1872–903. doi: 10.3390/molecules20021872 25625682
20. Rojo-Arreola L, Long T, Asarnow D, Suzuki BM, Singh R, Caffrey CR, Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS ONE. 2014;9(1):e87594. doi: 10.1371/journal.pone.0087594 24489942
21. Fonseca NC, da Cruz LF, da Silva Villela F, do Nascimento Pereira GA, de Siqueira-Neto JL, Kellar D, et al. Synthesis of a Sugar-Based Thiosemicarbazone Series and Structure-Activity Relationship versus the Parasite Cysteine Proteases Rhodesain, Cruzain, and Schistosoma mansoni Cathepsin B1. Antimicrob Agents Chemother. 2015;59(5):2666–77. doi: 10.1128/AAC.04601-14 25712353
22. Kaiser M, Maes L, Tadoori LP, Spangenberg T, Ioset JR, Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids. J Biomol Screen. 2015;20(5):634–45. doi: 10.1177/1087057115569155 25690568
23. Patel G, Roncal NE, Lee PJ, Leed SE, Erath J, Rodriguez A, et al. Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery. MedChemComm. 2014;5(5):655–8. 24910766
24. Morel M, Vanderstraete M, Cailliau K, Lescuyer A, Lancelot J, Dissous C, Compound library screening identified Akt/PKB kinase pathway inhibitors as potential key molecules for the development of new chemotherapeutics against schistosomiasis. Int J Parasitol Drugs Drug Resist. 2014;4(3):256–66. doi: 10.1016/j.ijpddr.2014.09.004 25516836
25. Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ, Jr. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat Chem Biol. 2006;2(8):415–6. 16816845
26. Andrade LF, Nahum LA, Avelar LG, Silva LL, Zerlotini A, Ruiz JC, et al. Eukaryotic protein kinases (ePKs) of the helminth parasite Schistosoma mansoni. BMC Genomics. 2011;12:215. doi: 10.1186/1471-2164-12-215 21548963
27. Doerig C, Grevelding CG, Targeting kinases in Plasmodium and Schistosoma: Same goals, different challenges. Biochim Biophys Acta. 2015.
28. Beckmann S, Leutner S, Gouignard N, Dissous C, Grevelding CG, Protein kinases as potential targets for novel anti-schistosomal strategies. Curr Pharm Des. 2012;18(24):3579–94. 22607148
29. Guidi A, Mansour NR, Paveley RA, Carruthers IM, Besnard J, Hopkins AL, et al. Application of RNAi to Genomic Drug Target Validation in Schistosomes. PLoS Negl Trop Dis. 2015;9(5):e0003801. doi: 10.1371/journal.pntd.0003801 25992548
30. Strebhardt K, Becker S, Matthess Y, Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery. Expert Opin Drug Discov. 2015;10(1):1–8. doi: 10.1517/17460441.2015.962510 25263688
31. Garuti L, Roberti M, Bottegoni G, Polo-like kinases inhibitors. Curr Med Chem. 2012;19(23):3937–48. 22709006
32. Gjertsen BT, Schoffski P, Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 2015;29(1):11–9. doi: 10.1038/leu.2014.222 25027517
33. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol. 2007;17(4):304–15. 17291761
34. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007;17(4):316–22. 17291758
35. Yuan J, Sanhaji M, Kramer A, Reindl W, Hofmann M, Kreis NN, et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol. 2011;179(4):2091–9. doi: 10.1016/j.ajpath.2011.06.031 21839059
36. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T, A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem. 2009;10(7):1145–8. doi: 10.1002/cbic.200900059 19350612
37. Long T, Vanderstraete M, Cailliau K, Morel M, Lescuyer A, Gouignard N, et al. SmSak, the second Polo-like kinase of the helminth parasite Schistosoma mansoni: conserved and unexpected roles in meiosis. PLoS ONE. 2012;7(6):e40045. doi: 10.1371/journal.pone.0040045 22768216
38. Dissous C, Grevelding CG, Long T, Schistosoma mansoni Polo-like kinases and their function in control of mitosis and parasite reproduction. An Acad Bras Cienc. 2011;83(2):627–35. 21670883
39. Long T, Cailliau K, Beckmann S, Browaeys E, Trolet J, Grevelding CG, et al. Schistosoma mansoni Polo-like kinase 1: A mitotic kinase with key functions in parasite reproduction. Int J Parasitol. 2010;40(9):1075–86. doi: 10.1016/j.ijpara.2010.03.002 20350550
40. Archambault V, Lepine G, Kachaner D, Understanding the Polo Kinase machine. Oncogene. 2015.
41. Archambault V, Glover DM, Yeast Polo-like kinase substrates are nailed with the right tools. Genome Biol. 2008;9(1):203. doi: 10.1186/gb-2008-9-1-203 18254925
42. Archambault V, Glover DM, Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol. 2009;10(4):265–75. doi: 10.1038/nrm2653 19305416
43. Barr FA, Sillje HH, Nigg EA, Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol. 2004;5(6):429–40. 15173822
44. Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M, Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol. 2014;15(7):433–52. doi: 10.1038/nrm3819 24954208
45. Strebhardt K, Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010;9(8):643–60. doi: 10.1038/nrd3184 20671765
46. de Carcer G, Manning G, Malumbres M, From Plk1 to Plk5: functional evolution of polo-like kinases. Cell cycle. 2011;10(14):2255–62. 21654194
47. Cheng L, Wang C, Jing J, Polo-like kinase 1 as a potential therapeutic target for osteosarcoma. Curr Pharm Des. 2015;21(10):1347–50. 25345614
48. Craig SN, Wyatt MD, McInnes C, Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014;9(7):773–89. doi: 10.1517/17460441.2014.918100 24819909
49. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I, Polo-like kinases (Plks) and cancer. Oncogene. 2005;24(2):287–91. 15640844
50. Elkins JM, Fedele V, Szklarz M, Abdul Azeez KR, Salah E, Mikolajczyk J, et al. Nat Biotechnol. 2015 Oct 26.
51. Emmitte KA, Andrews CW, Badiang JG, Davis-Ward RG, Dickson HD, Drewry DH, et al. Discovery of thiophene inhibitors of polo-like kinase. Bioorg Med Chem Lett. 2009;19(3):1018–21. doi: 10.1016/j.bmcl.2008.11.041 19097784
52. Emmitte KA, Adjabeng GM, Andrews CW, Alberti JG, Bambal R, Chamberlain SD, et al. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding. Bioorg Med Chem Lett. 2009;19(6):1694–7. doi: 10.1016/j.bmcl.2009.01.094 19237286
53. Rheault TR, Donaldson KH, Badiang-Alberti JG, Davis-Ward RG, Andrews CW, Bambal R, et al. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties. Bioorg Med Chem Lett. 2010;20(15):4587–92. doi: 10.1016/j.bmcl.2010.06.009 20594842
54. Abdulla MH, Lim KC, Sajid M, McKerrow JH, Caffrey CR, Schistosomiasis mansoni: novel chemotherapy using a cysteine protease inhibitor. PLoS Med. 2007;4(1):e14. 17214506
55. Abdulla MH, Ruelas DS, Wolff B, Snedecor J, Lim KC, Xu F, et al. Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis. 2009;3(7):e478. doi: 10.1371/journal.pntd.0000478 19597541
56. Colley DG, Wikel SK, Schistosoma mansoni: simplified method for the production of schistosomules. Exp Parasitol. 1974;35(1):44–51. 4815018
57. Stefanic S, Dvorak J, Horn M, Braschi S, Sojka D, Ruelas DS, et al. RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. PLoS Negl Trop Dis. 2010;4(10):e850. doi: 10.1371/journal.pntd.0000850 20976050
58. Duvall RH, DeWitt WB, An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg. 1967;16(4):483–6. 4952149
59. Basch PF, Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. J Parasitol. 1981;67(2):179–85. 7241277
60. Dvorak J, Mashiyama ST, Sajid M, Braschi S, Delcroix M, Schneider EL, et al. SmCL3, a gastrodermal cysteine protease of the human blood fluke Schistosoma mansoni. PLoS Negl Trop Dis. 2009;3(6):e449. doi: 10.1371/journal.pntd.0000449 19488406
61. Livak KJ, Schmittgen TD, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–8. 11846609
62. Beckmann S, Long T, Scheld C, Geyer R, Caffrey CR, Grevelding CG, Serum albumin and alpha-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib. Int J Parasitol Drugs Drug Resist. 2014;4(3):287–95. doi: 10.1016/j.ijpddr.2014.07.005 25516839
63. Singh R, Pittas, M., I. Heskia, I., Xu, F., McKerrow, J. H., Caffrey, C. R. Automated image-based phenotypic screening for high-throughput drug discovery. IEEE Symposium on Computer-Based Medical Systems 2–5 August 2009 Albuquerque, NM 2009. p. 1–8.
64. Asarnow D, Singh R, Segmenting the etiological agent of schistosomiasis for high-content screening. IEEE Transactions on Medical Imaging; Vol. 32, No. 6, pp. 1007–10018, 2013 doi: 10.1109/TMI.2013.2247412 23428618
65. Moody-Davis A, Mennillo L., Singh R., Region-Based Segmentation of Parasites for High-throughput Screening. International Symposium on Visual Computing (ISVC): Lecture Notes in Computer Science. Vol. 6938, pp. 44–54 Springer; 2011.
66. Saha U, Singh R, SpringerVision-based tracking of complex macroparasites for high-content phenotypic drug screening. Proceedings of the International Symposium on Visual Computing, Lecture Notes in Computer Science; Vol. 7432, pp. 104–114, 2012:
67. Lee H, Moody-Davis A, Saha U, Suzuki BM, Asarnow D, Chen S, et al. Quantification and clustering of phenotypic screening data using time-series analysis for chemotherapy of schistosomiasis. BMC Genomics. 2012;13 Suppl 1:S4.
68. Paveley RA, Mansour NR, Hallyburton I, Bleicher LS, Benn AE, Mikic I, et al. Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis. 2012;6(7):e1762. doi: 10.1371/journal.pntd.0001762 22860151
69. Asarnow D, Rojo-Arreola L, Suzuki BM, Caffrey CR, Singh R, The QDREC web server: determining dose-response characteristics of complex macroparasites in phenotypic drug screens. Bioinformatics. 2015;31(9):1515–8. doi: 10.1093/bioinformatics/btu831 25540182
70. Glaser J, Schurigt U, Suzuki BM, Caffrey CR, Holzgrabe U, Anti-Schistosomal Activity of Cinnamic Acid Esters: Eugenyl and Thymyl Cinnamate Induce Cytoplasmic Vacuoles and Death in Schistosomula of Schistosoma mansoni. Molecules. 2015;20(6):10873–83. doi: 10.3390/molecules200610873 26076109
71. Jain R, Dubes RC, Algorithms for Clustering Data. Englewood Cliffs, New Jersey: Prentice Hall; 1988.
72. Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, et al. Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia. J Pharmacol Exp Ther. 2015;352(3):579–89. doi: 10.1124/jpet.114.221150 25576074
73. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009;15(9):3094–102. doi: 10.1158/1078-0432.CCR-08-2445 19383823
74. Janning M, Fiedler W, Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development. Future Oncol. 2014;10(7):1157–65. doi: 10.2217/fon.14.53 24947257
75. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res. 2009;69(17):6969–77. doi: 10.1158/0008-5472.CAN-09-0945 19690138
76. Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, et al. Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther. 2010;9(7):2079–89. doi: 10.1158/1535-7163.MCT-10-0095 20571075
77. Reindl W, Yuan J, Kramer A, Strebhardt K, Berg T, Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol. 2008;15(5):459–66. doi: 10.1016/j.chembiol.2008.03.013 18482698
78. Ramirez B, Bickle Q., Yousif F., Fakorede F., Mouries M-A., Nwaka S., Schistosomes: challenges in compound screening. Expert Opin Drug Discov. 2007;2:S53–S61. doi: 10.1517/17460441.2.S1.S53 23489033
79. Ingram-Sieber K, Cowan N, Panic G, Vargas M, Mansour NR, Bickle QD, et al. Orally active antischistosomal early leads identified from the open access malaria box. PLoS Negl Trop Dis. 2014;8(1):e2610. doi: 10.1371/journal.pntd.0002610 24416463
80. Swierczewski BE, Davies SJ, A schistosome cAMP-dependent protein kinase catalytic subunit Is essential for parasite viability. PLoS Negl Trop Dis. 2009;3(8):e505. doi: 10.1371/journal.pntd.0000505 19707280
81. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 2007;4(6):e206. 17579510
82. Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther. 2007;6(2):450–9. 17267659
83. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011;17(10):3420–30. doi: 10.1158/1078-0432.CCR-10-2946 21459796
84. Ross-Macdonald P, Drug discovery without a molecular target: the road less traveled. Expert Rev Mol Diagn. 2007;7(1):1–4. 17187477
85. Swinney DC, Anthony J, How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507–19. doi: 10.1038/nrd3480 21701501
86. Eder J, Sedrani R, Wiesmann C, The discovery of first-in-class drugs: origins and evolution. Nat Rev Drug Discov. 2014;13(8):577–87. doi: 10.1038/nrd4336 25033734
87. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ, Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. J Med Chem. 2012;55(10):4527–38. doi: 10.1021/jm201649s 22409666
88. Caffrey CR, Parasitic Helminths: Targets, Screens, Drugs and Vaccines. Weinheim: Wiley-Blackwell; 2012.